The frontotemporal dementia (FTD) spectrum of neurodegenerative disorders includes a
heterogeneous group of conditions. However, following on from a series of important …

The recent commercialisation of the first disease-modifying drugs for Alzheimer's disease
emphasises the need for consensus recommendations on the rational use of biomarkers to …

With the inexorable aging of the global populace, neurodegenerative diseases (NDs) like
Alzheimer's disease (AD), Parkinson's disease (PD), and amyotrophic lateral sclerosis (ALS) …

Background Heterozygous loss-of-function mutations in the progranulin (PGRN) gene
(GRN) cause a reduction in PGRN and lead to the development of frontotemporal dementia …

The presymptomatic stages of frontotemporal dementia (FTD) are still poorly defined and
encompass a long accrual of progressive biological (preclinical) and then clinical …

Amyotrophic Lateral Sclerosis (ALS) and Frontotemporal dementia (FDT) are progressive
neurodegenerative disorders that, in several cases, overlap in clinical presentation, and …

TDP-43 is the primary or secondary pathological hallmark of neurodegenerative diseases,
such as amyotrophic lateral sclerosis, half of frontotemporal dementia cases, and limbic age …

Long‐term or severe lack of protective factors is important in the pathogenesis of
neurodegenerative dementia. Progranulin (PGRN), a neurotrophic factor expressed mainly …

Frontotemporal dementia (FTD) is one of the most common neurodegenerative diseases,
encompassing a myriad of different, clinically distinct subtypes which all target the …

Biomarkers in cerebrospinal fluid (CSF) are useful in the differential diagnosis between
frontotemporal dementia (FTD) and Alzheimer's dementia (AD), but require lumbar puncture …